- $1.35bn
- $3.24bn
- $279.86m
- 51
- 39
- 38
- 38
R2019 December 31st | R2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 357 | 307 | 195 | 233 | 280 |
Cost of Revenue | |||||
Gross Profit | 208 | 168 | 99.2 | 122 | 157 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 372 | 352 | 306 | 266 | 316 |
Operating Profit | -15.1 | -44.9 | -111 | -32.3 | -36.1 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 253 | -121 | -157 | -39.5 | -157 |
Provision for Income Taxes | |||||
Net Income After Taxes | 253 | -121 | -157 | -39.5 | -157 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 112 | -51.4 | -119 | -52.1 | -107 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 96.4 | -63.2 | -126 | -57.5 | -112 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.18 | -1.43 | -0.99 | -1.17 | -1.32 |
Dividends per Share |